Page 21 - Read Online
P. 21

Yu et al. Hepatoma Res. 2025;11:29 | https://dx.doi.org/10.20517/2394-5079.2025.47  Page 11 of 12

               Availability of data and materials
               All the data included in this study are available upon request from the corresponding author.

               Financial support and sponsorship
               None.

               Conflicts of interest
               All authors declared that there are no conflicts of interest.

               Ethical approval and consent to participate
               All procedures performed in studies involving human participants were in accordance with the ethical
               standards of the institutional and/or national research committee and with the 1964 Helsinki declaration
               and its later amendments or comparable ethical standards. The Ethics Committee of Jiangsu Cancer
               Hospital has approved this research (2022-076). Informed consent has been obtained from all participants.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2025.


               REFERENCES

               1.  Tu J, Wang B, Wang X, et al. Current status and new directions for hepatocellular carcinoma diagnosis. Liver Res. 2024;8:218-36. DOI
                   PubMed PMC
               2.  Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol.
                   2022;76:681-93. DOI PubMed PMC
               3.  Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, Version 2.2021, NCCN Clinical Practice Guidelines in
                   Oncology. J Natl Compr Canc Netw. 2021;19:541-65. DOI PubMed
               4.  Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151-72. DOI
                   PubMed
               5.  Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). Liver Cancer.
                   2023;12:405-44. DOI PubMed PMC
               6.  Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and
                   recommendations 2021 update. Liver Cancer. 2021;10:181-223. DOI PubMed PMC
               7.  Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol.
                   2023;14:1167975. DOI PubMed PMC
               8.  Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl
                   Lung Cancer Res. 2015;4:560-75. DOI PubMed PMC
               9.  Okiyama N, Tanaka R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol Int.
                   2022;71:169-78. DOI PubMed
               10.  Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-related adverse events: a
                   practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022;13:779691.
                   DOI PubMed PMC
               11.  Hartl L, Simbrunner B, Jachs M, et al. Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher
                   risk of acute-on-chronic liver failure, and mortality. JHEP Rep. 2024;6:100954. DOI PubMed PMC
               12.  Hasa E, Hartmann P, Schnabl B. Liver cirrhosis and immune dysfunction. Int Immunol. 2022;34:455-66. DOI PubMed PMC
               13.  Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and consequences of innate immune dysfunction in cirrhosis. Front Immunol.
                   2019;10:293. DOI PubMed PMC
   16   17   18   19   20   21   22   23   24   25   26